Editas Medicine, Inc.

Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms. Its work is centered on preclinical and early clinical programs, plus collaborations and licensing deals that generate most of its current revenue while it advances therapies for genetic and other serious diseases.

−381,9 %

−395,0 %

+25,4 %

3.54

3.54

— Editas Medicine, Inc.
%
Therapeutic gene-editing programs20% Preclinical and early clinical CRISPR medicines designed to treat serious genetic and other diseases.
Collaborations and milestones70% Revenue from partner-funded development work, option packages, and milestone payments, mainly with BMS.
Licensing fees10% Annual and upfront license fees from technology access agreements such as the Vertex license.

Editas does not sell approved medicines today; its economic customers are pharmaceutical partners, licensees, and...

  • Pharmaceutical collaboration partnersprimary

    Large biopharma companies that pay for access to Editas' CRISPR platforms, development work, and option rights.

  • Licensees of gene-editing IPprimary

    Companies such as Vertex that pay upfront or annual fees to use Editas-linked intellectual property and technology.

  • Future treating physicians and patientsemerging

    If programs are approved, hospitals, specialists, and patients in rare disease and liver indications would use the medicines.

  • Research collaboratorssecondary

    Academic and industry partners that use Editas' platform technologies in partnered discovery and development programs.

Editas is headquartered in the United States and conducts most of its research, development, and corporate activity...

  • •Headquartered and primarily operated in the United States
  • •Revenue is driven by U.S.-based collaboration and license agreements
  • •No owned manufacturing facilities; relies on third parties
  • •European patent disputes create foreign legal exposure
  • •Future commercialization would likely require global partner reach

Editas is shifting toward a narrower, capital-efficient pipeline built around EDIT-401 and other preclinical...

01
Advance EDIT-401 into clinical developmentshort-term

The company needs a lead program to create future product value and validate its gene-editing platform.

02
Expand partnered and licensed revenueshort-term

Collaboration and license income currently funds operations and reduces dependence on product sales.

03
Strengthen delivery and platform capabilitiesmedium-term

Effective delivery is a key bottleneck in in vivo gene editing and can improve program success rates.

04
Preserve capital and simplify operationsshort-term

As a preclinical biotech with no product sales, runway management is critical to avoid dilution and program delays.

Editas faces the classic risks of an early-stage gene-editing biotech: clinical failure, regulatory delay, and...

critical

Clinical development failure

The company is still preclinical/early clinical, so program outcomes are highly uncertain.

Scope
EDIT-401 and other programs may never reach approval.
Materiality
high
high

Intellectual property disputes

Some in-licensed patents face priority and validity challenges in the U.S. and Europe.

Scope
Could force licensing, delay programs, or prevent commercialization.
Materiality
high
high

Funding and liquidity risk

The company does not expect meaningful recurring product revenue in the near term.

Scope
May need additional capital before commercialization.
Materiality
high
high

Partner concentration

Substantially all current revenue is expected from Vertex, BMS, and future collaborations.

Scope
Loss or slowdown of a partner would reduce revenue and runway.
Materiality
high
medium

Competition in gene editing

Many large and well-funded biotech and pharma companies are pursuing similar indications.

Scope
Competitors may reach the market first or develop better therapies.
Materiality
medium
Revenue recognition for collaborations
Affects reported revenue timing and deferred revenue balances
Deferred revenue
Impacts future revenue recognition and balance sheet liabilities
Restructuring and impairment charges
Can materially distort operating expense trends and comparability
License fee accounting
Creates recurring revenue that is not tied to product sales

LISATA THERAPEUTICS, INC.

LSTA · Pharmaceutical Preparations

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

Prime Medicine, Inc.

PRME · Biological Products, (No Diagnostic Substances)

CRISPR Therapeutics AG

CRSP · Biological Products, (No Diagnostic Substances)

MetaVia Inc.

MTVA · Pharmaceutical Preparations

Korro Bio, Inc.

KRRO · Pharmaceutical Preparations

: 28/04/2026